Antibiotic treatment attenuates behavioral and neurochemical changes induced by exposure of rats to group a streptococcal antigen

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Lotan, Dafna ^a   Cunningham, Madeleine ^b   Joel, Daphna ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; IMMUNOGLOBULIN G; STREPTOCOCCUS ANTIGEN; TYROSINE 3 MONOOXYGENASE; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BEHAVIOR DISORDER; CLINICAL EVALUATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL BEHAVIORAL TEST; FOOD MANIPULATION ASSAY; FORCED SWIM TEST; MALE; MARBLE BURYING TEST; MOTOR DYSFUNCTION; NEUROCHEMISTRY; NONHUMAN; OUTCOME ASSESSMENT; PREFRONTAL CORTEX; RAT; STREPTOCOCCUS PYOGENES; THALAMUS; TREATMENT RESPONSE; ANIMAL; ANIMAL BEHAVIOR; BRAIN; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGY; LEWIS RAT; METABOLISM; MICROBIOLOGY; PATHOLOGY; STREPTOCOCCAL INFECTIONS; SWIMMING;

AMPICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BEHAVIOR, ANIMAL; BRAIN; IMMUNOGLOBULIN G; MALE; RATS, INBRED LEW; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; SWIMMING; TYROSINE 3-MONOOXYGENASE;

EID: 84903555259     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101257     Document Type: Article

References (66)

1. Martin JM, Green M (2006) Group A streptococcus. Semin Pediatr Infect Dis 17: 140-148.
2. Cunningham MW (2000) Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 13: 470-511.
3. Dale RC (2005) Post-streptococcal autoimmune disorders of the central nervous system. Dev Med Child Neurol 47: 785-791.
4. Marques-Dias MJ, Mercadante MT, Tucker D, Lombroso P (1997) Sydenham's chorea. Psychiatr Clin North Am 20: 809-820.
5. Bonthius DJ, Karacay B (2003) Sydenham's chorea: not gone and not forgotten. Semin Pediatr Neurol 10: 11-19.
6. Gordon N (2009) Sydenham's chorea, and its complications affecting the nervous system. Brain Dev 31: 11-14.
7. Cunningham MW (2012) Streptococcus and rheumatic fever. Curr Opin Rheumatol 24: 408-416.
8. Kirvan CA, Swedo SE, Heuser JS, Cunningham MW (2003) Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 9: 914-920.
9. Kirvan CA, Swedo SE, Snider LA, Cunningham MW (2006) Antibody-mediated neuronal cell signaling in behavior and movement disorders. J Neuroimmunol 179: 173-179.
10. Snider LA, Lougee L, Slattery M, Grant P, Swedo SE (2005) Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders. Biol Psychiatry 57: 788-792.
11. Murphy TK, Kurlan R, Leckman J (2010) The immunobiology of Tourette's disorder, pediatric autoimmune neuropsychiatric disorders associated with Streptococcus, and related disorders: a way forward. J Child Adolesc Psychopharmacol 20: 317-331.
12. Ivanov, II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, et al. (2008) Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4: 337-349.
13. Brimberg L, Benhar I, Mascaro-Blanco A, Alvarez K, Lotan D, et al. (2012) Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology 37: 2076-2087.
14. Lotan D, Benhar I, Alvarez K, Mascaro-Blanco A, Brimberg L, et al. (2014) Behavioral and neural effects of intra-striatal infusion of anti-streptococcal antibodies in rats. Brain Behav Immun.
15. Linthicum DS, Munoz JJ, Blaskett A (1982) Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cell Immunol 73: 299-310.
16. Kolb B, Holmes C (1983) Neonatal motor cortex lesions in the rat: absence of sparing of motor behaviors and impaired spatial learning concurrent with abnormal cerebral morphogenesis. Behav Neurosci 97: 697-709.
17. Cryan JF, Valentino RJ, Lucki I (2005) Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29: 547-569.
18. Swedo SE, Leonard HL, Schapiro MB, Casey BJ, Mannheim GB, et al. (1993) Sydenham's chorea: physical and psychological symptoms of St Vitus dance. Pediatrics 91: 706-713.
19. Demiroren K, Yavuz H, Cam L, Oran B, Karaaslan S, et al. (2007) Sydenham's chorea: a clinical follow-up of 65 patients. J Child Neurol 22: 550-554.
20. Dale RC, Heyman I, Surtees RA, Church AJ, Giovannoni G, et al. (2004) Dyskinesias and associated psychiatric disorders following streptococcal infections. Arch Dis Child 89: 604-610.
21. Ridel KR, Lipps TD, Gilbert DL (2010) The prevalence of neuropsychiatric disorders in Sydenham's chorea. Pediatr Neurol 42: 243-248.
22. Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, et al. (1998) Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 155: 264-271.
23. Asbahr FR, Garvey MA, Snider LA, Zanetta DM, Elkis H, et al. (2005) Obsessive-compulsive symptoms among patients with Sydenham chorea. Biol Psychiatry 57: 1073-1076.
24. Dale RC, Merheb V, Pillai S, Wang D, Cantrill L, et al. (2012) Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 135: 3453-3468.
25. Kirvan CA, Swedo SE, Kurahara D, Cunningham MW (2006) Streptococcal mimicry and antibody-mediated cell signaling in the pathogenesis of Sydenham's chorea. Autoimmunity 39: 21-29.
26. Takeuchi Y, Miyamoto E, Fukunaga K (2002) Activation of the rat dopamine D2 receptor promoter by mitogen-activated protein kinase and Ca2+/ calmodulin-dependent protein kinase II pathways. J Neurochem 83: 784-796.
27. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, et al. (2010) Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 30: 5866-5875.
28. Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, et al. (2009) AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 65: 424-434.
29. Ganzinelli S, Borda T, Sterin-Borda L (2006) Regulation of m1 muscarinic receptors and nNOS mRNA levels by autoantibodies from schizophrenic patients. Neuropharmacology 50: 362-371.
30. van Coevorden-Hameete MH, de Graaff E, Titulaer MJ, Hoogenraad CC, Sillevis Smitt PA (2014) Molecular and cellular mechanisms underlying antineuronal antibody mediated disorders of the central nervous system. Autoimmun Rev 13: 299-312.
31. Doyle F, Cardoso F, Lopes L, Mendes M, Dias F, et al. (2012) Infusion of Sydenham's chorea antibodies in striatum with up-regulated dopaminergic receptors: a pilot study to investigate the potential of SC antibodies to increase dopaminergic activity. Neurosci Lett 523: 186-189.
32. Brooks BM, Hart CA, Coleman JW (2005) Differential effects of beta-lactams on human IFN-gamma activity. J Antimicrob Chemother 56: 1122-1125.
33. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, et al. (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433: 73-77.
34. Wei J, Pan X, Pei Z, Wang W, Qiu W, et al. (2012) The beta-lactam antibiotic, ceftriaxone, provides neuroprotective potential via anti-excitotoxicity and anti-inflammation response in a rat model of traumatic brain injury. J Trauma Acute Care Surg 73: 654-660.
35. Goodrich GS, Kabakov AY, Hameed MQ, Dhamne SC, Rosenberg PA, et al. (2013) Ceftriaxone treatment after traumatic brain injury restores expression of the glutamate transporter GLT-1, reduces regional gliosis, and reduces posttraumatic seizures in the rat. J Neurotrauma.
36. Melzer N, Meuth SG, Torres-Salazar D, Bittner S, Zozulya AL, et al. (2008) A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. PLoS One 3: e3149.
37. Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, et al. (2008) Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 153: 329-337.
38. Miller BR, Dorner JL, Bunner KD, Gaither TW, Klein EL, et al. (2012) Upregulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6/2 mouse model of Huntington's disease. J Neurochem 121: 629-638.
39. Thone-Reineke C, Neumann C, Namsolleck P, Schmerbach K, Krikov M, et al. (2008) The beta-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke. J Hypertens 26: 2426-2435.
40. Leung TC, Lui CN, Chen LW, Yung WH, Chan YS, et al. (2012) Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydro-xydopamine- lesioned rats. ACS Chem Neurosci 3: 22-30.
41. Nizzardo M, Nardini M, Ronchi D, Salani S, Donadoni C, et al. (2011) Betalactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms. Exp Neurol 229: 214-225.
42. Schliamser SE, Cars O, Norrby SR (1991) Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother 27: 405-425.
43. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, et al. (2007) Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2: 119-129.
44. Hooper LV, Littman DR, Macpherson AJ (2012) Interactions between the microbiota and the immune system. Science 336: 1268-1273.
45. Yokote H, Miyake S, Croxford JL, Oki S, Mizusawa H, et al. (2008) NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol 173: 1714-1723.
46. Wu HJ, Ivanov, II, Darce J, Hattori K, Shima T, et al. (2010) Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32: 815-827.
47. Nieuwenhuis EE, Visser MR, Kavelaars A, Cobelens PM, Fleer A, et al. (2000) Oral antibiotics as a novel therapy for arthritis: evidence for a beneficial effect of intestinal Escherichia coli. Arthritis Rheum 43: 2583-2589.
48. Diamond B, Huerta PT, Tracey K, Volpe BT (2011) It takes guts to grow a brain: Increasing evidence of the important role of the intestinal microflora in neuro- and immune-modulatory functions during development and adulthood. Bioessays 33: 588-591.
49. Cryan JF, Dinan TG (2012) Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13: 701-712.
50. Bercik P, Collins SM, Verdu EF (2012) Microbes and the gut-brain axis. Neurogastroenterol Motil 24: 405-413.
51. Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, et al. (2013) Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155: 1451-1463.
52. Millan MJ, Lejeune F, Gobert A, Brocco M, Auclair A, et al. (2000) S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther 295: 1206-1222.
53. Nishino R, Mikami K, Takahashi H, Tomonaga S, Furuse M, et al. (2013) Commensal microbiota modulate murine behaviors in a strictly contaminationfree environment confirmed by culture-based methods. Neurogastroenterol Motil.
54. Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, et al. (2007) In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 193: 121-136.
55. Kobayashi T, Hayashi E, Shimamura M, Kinoshita M, Murphy NP (2008) Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study. Psychopharmacology (Berl) 197: 567-580.
56. Calabro RS, Polimeni G, Gervasi G, Bramanti P (2011) Postthalamic stroke dystonic choreoathetosis responsive to tetrabenazine. Ann Pharmacother 45: e65.
57. Takahashi T, Kanamori H, Shigehara R, Takahashi SN, Tamura M, et al. (2012) Pure hemi-chorea resulting from an acute phase of contralateral thalamic lacunar infarction: a case report. Case Rep Neurol 4: 194-201.
58. Lee PH, Nam HS, Lee KY, Lee BI, Lee JD (1999) Serial brain SPECT images in a case of Sydenham chorea. Arch Neurol 56: 237-240.
59. Kassubek J, Juengling FD, Hellwig B, Spreer J, Lucking CH (2002) Thalamic gray matter changes in unilateral Parkinsonian resting tremor: a voxel-based morphometric analysis of 3-dimensional magnetic resonance imaging. Neurosci Lett 323: 29-32.
60. Citak EC, Gucuyener K, Karabacak NI, Serdaroglu A, Okuyaz C, et al. (2004) Functional brain imaging in Sydenham's chorea and streptococcal tic disorders. J Child Neurol 19: 387-390.
61. Hirjak D, Wolf RC, Stieltjes B, Seidl U, Schroder J, et al. (2012) Neurological soft signs and subcortical brain morphology in recent onset schizophrenia. J Psychiatr Res 46: 533-539.
62. Lee SJ, Lee WY, Kim YK, An YS, Cho JW, et al. (2012) Apparent relative hypermetabolism of selective brain areas in Huntington disease and importance of reference region for analysis. Clin Nucl Med 37: 663-668.
63. Maling N, Hashemiyoon R, Foote KD, Okun MS, Sanchez JC (2012) Increased thalamic gamma band activity correlates with symptom relief following deep brain stimulation in humans with Tourette's syndrome. PLoS One 7: e44215.
64. Samadi P, Boutet A, Rymar VV, Rawal K, Maheux J, et al. (2013) Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease. Genes Brain Behav 12: 108-124.
65. Saydoff JA, Liu LS, Garcia RA, Hu Z, Li D, et al. (2003) Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease. Brain Res 994: 44-54.
66. Hansen N, Grunewald B, Weishaupt A, Colaco MN, Toyka KV, et al. (2013) Human Stiff person syndrome IgG-containing high-titer anti-GAD65 autoantibodies induce motor dysfunction in rats. Exp Neurol 239: 202-209.